Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerold Bepler

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Cancer|April 3, 2014
Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomasAlec E Vaezi, Gerold Bepler, Nikhil R Bhagwat, et al.
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancerScott J Antonia, Noweeda Mirza, Ingo Fricke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung CancerErica Hlavin Bell, Arup R Chakraborty, Xiaokui Mo, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institutionGeorge R Simon, John C Ruckdeschel, Charles Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancerEric B Haura, Tawee Tanvetyanon, Alberto Chiappori, et al.
Cancer|April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)Gerold Bepler, Ralph G Zinner, James Moon, et al.
Scientific Reports|October 31, 2018
Chronic p27<sup>Kip1</sup> Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid ReceptorMugdha Patki, Thomas McFall, Rayna Rosati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancerAlberto A Chiappori, Eric Haura, Francisco A Rodriguez, et al.
Oncotarget|July 25, 2018
A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancersVino T Cheriyan, Hashem Alsaab, Sreeja Sekhar, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Cancer|April 3, 2014
Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomasAlec E Vaezi, Gerold Bepler, Nikhil R Bhagwat, et al.
The American Journal of Pathology|January 13, 2011
ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysisGerold Bepler, Ken André Olaussen, Anne-Lise Vataire, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancerScott J Antonia, Noweeda Mirza, Ingo Fricke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2015
SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung CancerErica Hlavin Bell, Arup R Chakraborty, Xiaokui Mo, et al.
Cancer Control : Journal of the Moffitt Cancer Center|October 29, 2003
Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institutionGeorge R Simon, John C Ruckdeschel, Charles Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancerEric B Haura, Tawee Tanvetyanon, Alberto Chiappori, et al.
Cancer|April 23, 2014
A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)Gerold Bepler, Ralph G Zinner, James Moon, et al.
Scientific Reports|October 31, 2018
Chronic p27<sup>Kip1</sup> Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid ReceptorMugdha Patki, Thomas McFall, Rayna Rosati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2008
Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancerAlberto A Chiappori, Eric Haura, Francisco A Rodriguez, et al.
Oncotarget|July 25, 2018
A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancersVino T Cheriyan, Hashem Alsaab, Sreeja Sekhar, et al.
Pageof 16